Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.
Ustun C, Kim S, Chen M, Beitinjaneh AM, Brown VI, Dahi PB, Daly A, Diaz MA, Freytes CO, Ganguly S, Hashmi S, Hildebrandt GC, Lazarus HM, Nishihori T, Olsson RF, Page KM, Papanicolaou G, Saad A, Seo S, William BM, Wingard JR, Wirk B, Yared JA, Perales MA, Auletta JJ, Komanduri KV, Lindemans CA, Riches ML.
Ustun C, et al. Among authors: chen m.
Blood Adv. 2019 Sep 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226.
Blood Adv. 2019.
PMID: 31471322
Free PMC article.